TNF Pharmaceuticals, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Feb 2036
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 11, 2026The maintenance fee for Methods of increasing hair growth and improving hair appearance (US 10,314,775) comes due Dec 11, 2026. Unpaid by Jun 11, 2027, it lapses early.
- 1 fee due May 12, 2027The maintenance fee for Method of treating addictions to opioids (US 10,471,052) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
- 1 fee due Jun 30, 2027The maintenance fee for Methods of altering programmed cell death and extending cell life (US 10,517,856) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 2 fees due Sep 17 to 26, 2027 · next Sep 17
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,884,055 | Method of treating substance addictions In force · From the USPTO record | In force | From the USPTO record | |
| US 10,471,052 | Method of treating addictions to opioids In force · From the USPTO record | In force | From the USPTO record | |
| US 10,517,856 | Methods of altering programmed cell death and extending cell life In force · From the USPTO record | In force | From the USPTO record | |
| US 10,588,899 | Methods of treating diabetes In force · From the USPTO record | In force | From the USPTO record | |
| US 10,722,506 | Method of treating multiple sclerosis In force · From the USPTO record | In force | From the USPTO record | |
| US 10,786,493 | Method of treating viral infections In force · From the USPTO record | In force | From the USPTO record | |
| US 10,806,728 | Pharmaceutical salts of isomyosmine and pharmaceutical compositions containing same In force · From the USPTO record | In force | From the USPTO record | |
| US 10,835,523 | Method of regulating tumor necrosis factor-alpha (TNF-α) for treating cancers, autoimmune disorders, and other disorders associated with chronic inflammation In force · From the USPTO record | In force | From the USPTO record | |
| US 10,918,633 | Method of treating coronavirus In force · From the USPTO record | In force | From the USPTO record | |
| US 11,096,933 | Method of treating disorders associated with chronic inflammation In force · From the USPTO record | In force | From the USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.